May 26, 2010 (FinancialWire) (Investrend Research Syndicate) (Go to http://www.financialwire.net/?s=vlngnlv+updwngrds for more ValuEngine upgrade & research articles.) — ValuEngine, Inc., has upgraded Par Pharmaceutical Companies, Inc. (NYSE: PRX) to a "5" rating, the service’s highest. Company summary analytics and an industry research report by ValuEngine on PRX is available via the Investrend Research Syndicate (at http://www.valuengine.com/rep/searchsrep?pid=42&srchfor=PRX).

The ValuEngine Rating is an overall assessment of a stock's attractiveness. It combines the following five factors: ValuEngine’s proprietary valuation, risk-return tradeoff, momentum, market capitalization and ValuEngine’s proprietary forecasted one-month return.

Approximately 80 to 85 companies achieve this highest ValuEngine rating out of VE’s total coverage of over 5,000 publicly traded companies.

Par Pharmaceutical Companies, Inc., through its subsidiary, Par Pharmaceutical, Inc. engages in the development, manufacture, and distribution of generic and branded drugs in the United States.

ValuEngine is a subscription-based business intelligence, market and equity analysis firm that provides exclusive, customized research and analysis solutions directly to companies, investors, investment banks and broker-dealers. A special arrangement between the Investrend Research Syndicate and ValuEngine provides for preferred introductions and complimentary value-added services for those enrolling into ValuEngine programs. For more information, including the option to arrange a preferred introduction to ValuEngine, go to ValuEngine’s dedicated Investrend Syndications webpage (at http://www.investrend.com/valuengine).

The Investrend Research Syndicate (http://www.investrend.com/research/syndicate), a proprietary entity of Investrend Communications, Inc., distributes equity research-related information issued by sources that deemed to be dedicated to unbiased, reliable and transparent analytics. The primary measure for vetting those sources is the “Standards for Independent Research Providers” (http://www.investrend.com/FIRST/standards) as promulgated by the FIRST Research Consortium (http://www.investrend.com/FIRST).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (at http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website at http://www.financialwire.net/disclosures.php and http://www.financialwire.net/2010/04/23/safe-harbor/). Additional resources for investors are also accessible via the FinancialWire(tm) website (at http://www.financialwire.net/2010/04/23/investor-resources/). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

[ssryrsyr] [rsrchequty] [vlngnlv] [anlytcsct] [rtngsgnt] [updwngrds]